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http://www.molecular-cancer.com/content/13/1/165RESEARCH Open AccessHMGB1-mediated autophagy promotes docetaxel
resistance in human lung adenocarcinoma
Banzhou Pan†, Dongqin Chen†, Jiayuan Huang†, Rui Wang, Bing Feng, Haizhu Song* and Longbang Chen*Abstract
Background: Docetaxel resistance remains a major obstacle in the treatment of non-small cell lung cancer (NSCLC).
High-mobility group box 1 (HMGB1) has been shown to promote autophagy protection in response to antitumor
therapy, but the exact molecular mechanism underlying HMGB1-mediated autophagy has not been clearly defined.
Methods: Lung adenocarcinoma (LAD) cells were transfected with pcDNA3.1-HMGB1 or HMGB1 shRNA, followed by
docetaxel treatment. Cell viability and proliferation were tested by MTT assay and colony formation assay, respectively.
Annexin V flow cytometric analysis and western blot analysis of activated caspase3 and cleaved PARP were used to
evaluate apoptosis, while immunofluorescence microscopy and transmission electron microscopy were applied to
assess autophagy activity. The formation of the Beclin-1-PI3K-III complex was examined by immunoprecipitation
analysis. NOD/SCID mice were inoculated with docetaxel-resistant SPC-A1/DTX cells transfected with control or
HMGB1 shRNA.
Results: HMGB1 translocated from the nucleus to the cytoplasm in LAD cells exposed to docetaxel and acted as a
positive regulator of autophagy, which inhibited apoptosis and increased drug resistance. Suppression of HMGB1
restored the sensitivity of LAD cells to docetaxel both in vivo and in vitro. Mechanistic investigation revealed that
HMGB1 promoted the formation of the Beclin-1-PI3K-III complex through activating the mitogen-activated protein
kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling pathway, thereby regulating autophagosome
formation.
Conclusions: Our results demonstrated that HMGB1-regulated autophagy is a significant contributor to docetaxel
resistance in LAD cells. Suppression of HMGB1 or limiting HMGB1 cytosolic translocation diminished autophagic
protection in response to docetaxel in LAD cells.
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Lung cancer is the leading cause of cancer-related mor-
tality among malignancies worldwide. Lung adenocarcin-
oma (LAD) is the most common type of lung cancer,
and accounts for approximately 30–40% of non-small
cell lung cancer (NSCLC) cases [1]. In spite of signifi-
cant achievement in the treatment of LAD over the last
decade, the prognosis for patients with advanced disease
remains poor [2]. Docetaxel, a semi-synthetic analog of
paclitaxel, was granted approval as a first-line chemother-
apy regimen for NSCLC [3]. However, chemoresistance* Correspondence: songhaizhu@163.com; dr.chenlb@163.com
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unless otherwise stated.remains a major obstacle constraining the clinical applica-
tion of this agent.
Autophagy, a regulated process that consists of selective
degradation of cellular proteins and cytoplasmic organelles,
is implicated in many physiological and pathological condi-
tions, including intracellular recycling, energy homeostasis,
neurodegeneration and, importantly, cancer [4,5]. Studies
have shown a paradoxical dual effect of autophagy in
cancer development and progression. Inhibition of
autophagy promotes tumorigenesis [4], while induction of
autophagy in established tumors promotes cell survival
under nutrition starvation, cellular stress and antitumor
therapies [6,7]. Clarifying the mechanism that underlies
and regulates these distinct functions requires further
investigation [4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Docetaxel induced autophagy in LAD cells. (A) SPC-A1 and H1299 cells were treated with either the indicated concentrations of
docetaxel for 24 h or 10 μg/l docetaxel for varying periods. Whole cell lysates were subjected to western blot analysis for LC3, p62 and GAPDH
expression (as a loading control). (B) Both parental cells (SPC-A1 and H1299) and docetaxel-resistant cells (SPC-A1/DTX and H1299/DTX) were
transiently transfected with a GFP-LC3 construct. Twenty-four hours later, parental cells were exposed to docetaxel (10 μg/l) for an additional
24 h. GFP-LC3 dot formation was analyzed as described in Materials and Methods (mean ± S.D. of three independent experiments, *P < 0.05, **P < 0.01).
Bar = 50 μm. (C) SPC-A1 and H1299 cells pretreated with or without bafilomycin A1 (20 nM, 2 h) were exposed to docetaxel (10 μg/l) for an additional
24 h. Whole cell lysates were analyzed by western blot. (D, E) Parental cells (SPC-A1 and H1299) and docetaxel-resistant cells (SPC-A1/DTX and
H1299/DTX) were analyzed by (D) western blot analysis for LC3 and GAPDH expression and (E) transmission electron microscopy analysis, as
described in Materials and methods. A magnified view of the electron photomicrograph showed the characteristic autophagosomes. N: nucleus. The
results were obtained from three independent experiments.
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served non-histone nuclear protein that binds DNA and
promotes assembly of proteins on specific DNA targets
[8]. In addition to its role in the nucleus, HMGB1 also
functions in the cytoplasm as an extracellular signaling
protein during inflammation, cell differentiation and
tumor progression [9,10]. Upregulation of HMGB1
expression has been demonstrated in various solid tu-
mors and hematological malignancies, such as breast
cancer and lymphoma [11,12]. Cytosolic translocation
and HMGB1 release from tumor cells in response to
chemotherapy and radiotherapy is a vital characteristic
of the disordered tumor microenvironment [13,14].
Modification of HMGB1 localization has been shown
to link autophagy and apoptosis [8], but the exact mo-
lecular mechanism of HMGB1-mediated autophagy in
tumor therapy has not been clearly defined.
In this study, we found that cytosolic HMGB1 ex-
pression and associated autophagy levels increased rap-
idly in response to docetaxel treatment in LAD cells.
Downregulation of cytosolic HMGB1 levels limited
docetaxel-induced autophagic protection, which en-
hanced chemosensitivity of parental LAD cells and
even resensitized docetaxel-resistant LAD cells. Fur-
thermore, our data verified a role for HMGB1 in the
regulation of the Beclin1-PI3K-III complex through
the mitogen-activated protein kinase (MEK)-extracel-
lular signal-regulated kinase (ERK) pathway. Together
our data supports the notion that HMGB1 represents a
suitable target when combined with conventional che-
motherapies in LAD.
Results
Docetaxel induced a cytoprotective autophagy that
protects LAD cells from apoptosis
To assess the effect of docetaxel on autophagy and the
role of autophagy in determining the sensitivity of LAD
cells to docetaxel, first we evaluated autophagy activity
in SPC-A1 and H1299 cells after treatment with doce-
taxel. As shown in Figure 1A, western blot analysis
revealed that docetaxel treatment led to a dose- and
time-dependent increase in the level of LC3-II anddecrease in the amount of p62, two selective markers
of autophagy, in both SPC-A1 and H1299 cells. The ef-
fect of docetaxel on autophagy was next confirmed by a
GFP-LC3 punctate formation assay [15]. After transfecting
both cell lines with a GFP-LC3 plasmid, we observed an
abundance of punctate fluorescent dots after 24 h doce-
taxel treatment, which reflects the conversion from
cytoplasmic LC3-I to the phosphatidylethanolamine-
conjugated form LC3-II (Figure 1B). To further demon-
strate the activation of autophagy by docetaxel, we treated
cells with an autophagy-lysosomal inhibitor, bafilomycin
A1, 2 h prior to docetaxel treatment [15,16]. As displayed
in Figure 1C, in the presence of bafilomycin A1, LC3-II
levels were increased in both cell lines in comparison with
docetaxel alone treatment. We then analyzed autophagy
activity in two docetaxel-resistant cell lines, SPC-A1/DTX
and H1299/DTX, which were previously established in
our lab. The baseline levels of LC3-II were higher in
the docetaxel-resistant lines than in the parental cells
(Figure 1D). SPC-A1/DTX and H1299/DTX showed
increased autophagy activity as measured by analysis of
GFP-LC3 punctate formation using confocal microscopy
(Figure 1B) and by ultrastructural analysis of characteristic
autophagosomes using transmission electron microscopy
(Figure 1E).
Next, to determine whether docetaxel-induced au-
tophagy played a protective or resistant role in the
drug treatment, we treated SPC-A1 and H1299 cells
with an autophagy inhibitor, 3-methyladenine (3-MA),
or transfected cells with small-interfering RNA (siRNA)
specifically targeting the autophagic gene Atg5 before
addition of docetaxel. Both 3-MA and Atg5 siRNA effi-
ciently blocked activation of autophagy, which caused
an increase of cytotoxicity and apoptosis and decrease
in the proliferation rate of SPC-A1 and H1299 cells
(Figure 2A, 2C and 2E). Western blot analysis of c-caspase3
and c-PARP also confirmed the results (Additional file 1:
Figure S1A and S1B). However, the sensitivity of SPC-A1/
DTX and H1299/DTX cells to docetaxel was markedly
enhanced (Figure 2B) while the proliferation rate was
greatly diminished (Figure 2D) after addition of 3-MA
or silencing of Atg5. Moreover, both docetaxel-resistant
Figure 2 (See legend on next page.)
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Figure 2 Inhibition of autophagy enhanced sensitivity of LAD cells to docetaxel. (A, B) LAD cells were treated with 3-methyladenine (3-MA,
5 mM) or transiently transfected with Atg5 or control siRNA. Cells were exposed to the indicated concentrations of docetaxel for 48 h. Viable cells
were determined with an MTT assay as described in Materials and methods. (C, D) LAD cells were incubated with various concentrations of
docetaxel for 48 h in the presence or absence of 3-MA. The colonies were stained and counted, and survival curves were constructed from
three independent experiments. (E) SPC-A1 and H1299 cells were treated with docetaxel (10 μg/l) in the presence or absence of 3-MA (5 mM, 2 h) or
Atg5 siRNA. Apoptosis was determined by flow cytometric analysis of Annexin-V/PI staining. (F) SPC-A1/DTX cells were treated with the indicated doses
of docetaxel in the presence or absence of 3-MA or Atg5 siRNA. Apoptosis was determined by flow cytometric analysis of Annexin-V/PI staining. Each
point or bar represents mean ± S.D. of triplicate determinations. *P< 0.05, **P< 0.01 compared with docetaxel alone treatment.
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after inhibition of autophagy (Figure 2F, Additional file 1:
Figure S1C and S1D).
Taken together, these finding suggests that autophagy
is induced by docetaxel and functions as a docetaxel
resistance mechanism in LAD cells. Therefore, sup-
pression of autophagy might be a novel strategy for
circumventing the resistance of LAD cells to docetaxel.
Docetaxel promoted HMGB1 expression and cytosolic
translocation
To explore the potential role of HMGB1 in the regula-
tion of docetaxel-induced autophagy, we analyzed
HMGB1 protein expression and location in LAD cells
exposed to docetaxel (10 μg/l) for indicated periods of
time. Western blot analysis of nuclear and cytosolic
fractions of SPC-A1 and H1299 cells indicated that in
the absence of treatment, HMGB1 was mainly located
in the nucleus, with very low levels in the cytoplasm.
Docetaxel markedly enhanced total levels of HMGB1
in both parental cells in a time-dependent manner.
Moreover, following exposure to docetaxel, cytosolic
levels were elevated at 6 h and kept rising until 48 h,
while the nuclear levels were reduced at the same time.
Accumulation of LC3-II showed an obvious elevation
after treatment with docetaxel for 6 h, and continued
to increase until 48 h (Figure 3A and Additional file 2:
Figure S2A). Notably, ethyl pyruvate (EP), a pharmaco-
logical inhibitor of HMGB1 cytoplasmic translocation
[7], attenuated docetaxel-induced autophagy, as shown
in Figure 3B and Additional file 2: Figure S2B. Further-
more, diminished cytosolic HMGB1 also limited the
activation of autophagy even in cells transfected with
cDNA encoding full-length human HMGB1 (Figure 3C
and Additional file 2: Figure S2C).
The level of cytosolic HMGB1 exhibited a positive cor-
relation with docetaxel-induced autophagy. Meanwhile,
SPC-A1/DTX and H1299/DTX cells also showed rela-
tively higher total level of HMGB1 which included a
higher cytosolic level and a lower nuclear level under
basal conditions compared to parental cells (Figure 3D).
However, application of EP decreased LC3-II accumula-
tion (Figure 3E).HMGB1 altered sensitivity of LAD cells to docetaxel
To clarify the role of HMGB1 in LAD cells following
chemotherapy, we analyzed the responses of SPC-A1
and H1299 cells to docetaxel treatment with depleted
for HMGB1 expression. Knockdown of HMGB1 or lim-
iting HMGB1 cytosolic translocation in SPC-A1 and
H1299 cells enhanced the cellular response to docetaxel
(Figure 4A) and inhibited cell proliferation (Figure 4C).
Docetaxel induced apoptotic cell death to a great extent
after HMGB1 knockdown, as shown by an increase of
Annexin-V positive cells by 15.59 ± 1.01% and 12.79 ±
0.88% in SPC-A1 and H1299 cells, respectively (Figure 4E),
as well as increased level of activated caspase3 and
PARP cleavage (Additional file 3: Figure S3A). More-
over, treatment with an apoptosis inhibitor, Z-VAD-
fmk [17], reduced the activation of caspase3 (Additional
file 3: Figure S3A). Conversely, pretreatment with HMGB1
increased drug resistance in both parental LAD cells, as
displayed by an elevated cell survival rate. Nevertheless,
blockade of autophagy by 3-MA or Atg5 siRNA re-
versed HMGB1-induced protection against docetaxel
(Figure 4G).
The effect of HMGB1 gene silencing on enhancing
docetaxel sensitivity was even more biologically signi-
ficant in the docetaxel-resistant cells. Similar to the
results after pharmacologically inhibiting autophagy in
Figure 2A, transfection of SPC-A1/DTX and H1299/
DTX cells with HMGB1 shRNA rendered them largely
more sensitive to docetaxel, as indicated by a decrease in
the number of surviving cells (Figure 4B) and increase of
apoptosis (Additional file 3: Figure S3B). The proliferation
rate was also significantly reduced (Figure 4D). Import-
antly, addition of EP caused similar effects as knockdown
of HMGB1 (Figure 4B).
HMGB1 modulated docetaxel-induced autophagy in LAD
cells
To investigate whether HMGB1 is a direct activator of
autophagy, we evaluated the LC3-I to LC3-II conversion
and LC3 punctate formation by fluorescent analysis as
described above. Knockdown of HMGB1 by transfecting
SPC-A1 and H1299 cells with HMGB1 shRNA pre-
vented the appearance of LC3-II and the degradation of
Figure 3 (See legend on next page.)
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Figure 3 Docetaxel promoted HMGB1 expression and cytosolic translocation. (A) SPC-A1 cells were treated with docetaxel (10 μg/l) for the
indicated periods. Total cell lysates, nuclear extracts, cytoplasmic fractions and extracellular medium were prepared and HMGB1 levels were
analyzed by western blot. (B) SPC-A1 cells were pretreated with or without ethyl pyruvate (EP, 10 mM, 1 h) before addition of docetaxel (10 μg/l) for
48 h. Whole cell lysates, nuclear extracts and cytoplasmic fractions were analyzed by western blot for HMGB1. (C) SPC-A1 cells transfected with
pcDNA3.1-HMGB1 or control vector were treated with EP (10 mM, 1 h). Total cell lysates, nuclear extracts, cytoplasmic fractions were analyzed
by western blot for HMGB1. (D) Total cell lysates, nuclear extracts, and cytoplasmic fractions from parental and docetaxel-resistance LAD cells
were analyzed by western blot for HMGB1. (E) Western blot analysis of HMGB1 in the presence or absence of EP (10 mM, 1 h) in SPC-A1/DTX
and H1299/DTX cells. GAPDH was used as a loading control for whole cell lysates, extracellular medium and cytoplasmic extracts, and H2A was
used as a loading control for nuclear extracts. The experiments were performed in triplicate. H1299 cells were subjected to the analyses as above and
the results are shown in Additional file 2: Figure S2.
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downregulation of HMGB1 expression or inhibition of
cytosolic translocation of HMGB1 with EP decreased the
level of LC3-II in SPC-A1/DTX and H1299/DTX cells,
and a high dose of docetaxel failed to induce LC3-II
turnover to a greater degree (Figure 6A and 6B). In
contrast, overexpression of HMGB1 significantly increased
LC3-II accumulation and autophagic p62 degradation.
However, this elevated conversion of LC3-I to LC3-II
could be abolished by suppression of autophagy with
3-MA (Figure 5B). Fluorescence micrographs showed a
punctate pattern of GFP-LC3 in HMGB1-overexpressing
SPC-A1 and H1299 cells, which could be greatly attenu-
ated by application of 3-MA (Figure 5C). Meanwhile,
compared with the vector control groups, SPC-A1/DTX
and H1299/DTX cells transfected with HMGB1 shRNA
exhibited reduced formation of GFP-LC3 punctate stain-
ing after docetaxel treatment (Figure 6C). These data
support a vital role for HMGB1 in the regulation of
autophagy in LAD cells.
mTORC1 dependent pathway was not required for
HMGB1-mediated autophagy in LAD cells
Accumulating evidence has demonstrated that inhibition
of the Akt/mTORC1 pathway is linked to the trigger
for autophagy [18,19]. mTOR, a downstream effector of
Akt, plays a critical role in the regulation of protein
synthesis by phosphorylation of p70S6K (70 kDa riboso-
mal protein S6 kinase) [20]. Thus, we sought to test
whether HMGB1 could regulate docetaxel-induced au-
tophagy through the Akt/mTORC1 pathway in LAD cells.
SPC-A1 cells overexpressing HMGB1 showed no
distinct change in the level of phosphor-Akt(Ser473),
phosphor-mTOR(Ser2448), phosphor-S6RP (Additional
file 4: Figure S4A), nor did the docetaxel-resistant SPC-
A1/DTX cells transfected with HMGB1 shRNA (Additional
file 4: Figure S4B).
Suppression of mTORC1 activity is considered as a cru-
cial step in the initiation of autophagy [21]. Additionally,
rapamycin, a specific inhibitor of mTORC1 [22], enhanced
the accumulation of LC3-II in SPC-A1 cells transfected
with the control vector but not in cells transfected withHMGB1 shRNA (Additional file 4: Figure S4C). In addition,
siRNA-mediated silencing of mTORC1 conferred less
protection in HMGB1 knockdown cells due to lessened
autophagy activity (Additional file 4: Figure S4D). Col-
lectively, these results indicated that HMGB1 might not
regulate autophagy through a mTORC1-dependent path-
way in LAD cells.
HMGB1 promoted Beclin-1-PI3K-III core complex
formation through the MEK/ERK1/2 pathway
As shown in Figure 5B, we found that 3-MA, a potent
PI3K inhibitor, markedly inhibited HMGB1-induced LC3-
II conversion. Thus, we tested whether PI3K-III, which
had been reported to help promote autophagy initiation
[4,23], was required for HMGB1-induced autophagy. To
exclude the effect of 3-MA on other kinases and cellular
processes, siRNA specifically targeting PI3K-III was trans-
fected into SPC-A1 cells. Figure 7A showed that reduction
of PI3K-III expression in these cells distinctly inhibited
HMGB1-induced autophagy, implying that PI3K-III is
required for HMGB1-mediated autophagy.
We next evaluated the role of the MEK-ERK1/2 path-
way in HMGB1-induced autophagy, in which MEK func-
tions as an immediate upstream activator of ERK1/2.
Transfection of SPC-A1 cells with an HMGB1 cDNA
plasmid activated the MEK-ERK1/2 pathway by increas-
ing the phosphorylation of ERK1/2. However, pharmaco-
logical disruption of the MEK-ERK1/2 pathway by the
specific inhibitor PD098059 that prevents ERK1/2 acti-
vation (Figure 7B) or by transfection with MEK siRNA
(Figure 7C) reduced HMGB1-induced LC3-II formation
and p62 degradation. Notably, suppression of PI3K-III
also inhibited HMGB1-induced phosphorylation of the
MEK-ERK1/2 pathway, suggesting that MEK-ERK1/2 is
a downstream signal from PI3K-III (Figure 7A). More-
over, transfection of SPC-A1 cells with MEK1-DD, the
constitutively active form of MEK1, an upstream activa-
tor of ERK, relieved autophagy inhibition mediated by
HMGB1 (Figure 7D).
The Beclin-1-PI3K-III core complex is essential for
vesicle nucleation in autophagic stages [24]. Transfection
with pcDNA3.1-HMGB1 enhanced the formation of the
Figure 4 (See legend on next page.)
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Figure 4 HMGB1 altered the sensitivity of LAD cells to docetaxel in vitro. Parental and docetaxel-resistant LAD cells were transfected with
HMGB1 shRNA or pretreated with EP before incubation with indicated concentrations of docetaxel for 48 h. (A, B) Cell viability was analyzed by
MTT assay. (C, D) Cell proliferation was evaluated by colony formation assay. (E, F) Apoptosis was analyzed by flow cytometric analysis of
Annexin-V/PI staining. (G) SPC-A1 cells transfected with pcDNA3.1 control or pcDNA3.1-HMGB1 were exposed to indicated doses of docetaxel for
48 h in the presence or absence of 3-MA (5 mM) or Atg5 siRNA. Cell viability was analyzed by MTT assay. The results shown are the representative
of three identical experiments, and the bars are the mean ± S.D. *P < 0.05, **P < 0.01.
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blocked the interaction between Beclin1 and PI3K-III in
SPC-A1 cells (Figure 7E). Conversely, transfection of
the active MEK construct, which conferred resistance to
the suppression of MEK-ERK1/2 pathway phosphoryl-
ation, eliminated the negative control of Beclin-1-PI3K-
III complex formation by HMGB1 (Figure 7F). These
studies suggest that the MEK-ERK1/2 pathway is re-
quired for HMGB1-induced formation of the Beclin-1-
PI3K-III complex.
Downregulation of HMGB1 enhanced the response of
SPC-A1/DTX cells to docetaxel in vivo
To test the effects of targeted downregulation of HMGB1
on chemosensitivity of LAD cells in vivo, we inoculated
NOD/SCID mice with SPC-A1/DTX cells transfected with
HMGB1 shRNA. Tumors derived from HMGB1 shRNA-
transfected SPC-A1/DTX cells grew more slowly com-
pared with those derived from control shRNA-transfected
cells after being treated with docetaxel (Figure 8A and B).
Immunohistochemistry analysis showed that the positive
rate of PCNA in the HMGB1 shRNA-transfected group
was greatly diminished (Figure 8C). TUNEL staining of
resected tumor tissues also revealed even lower apoptosis
in the HMGB1 shRNA group than the control group. We
also observed a decreased level of LC3-II expression in
HMGB1 shRNA-transfected tumors in response to do-
cetaxel in comparison with control shRNA-transfected
tumors (Figure 8D). These results support the critical
role of HMGB1 in modulating the chemosensitivity in
docetaxel-resistant LAD cells in vivo.
Discussion
In this study, we demonstrated that HMGB1-regulated
autophagy is a significant contributor to docetaxel resist-
ance in LAD cells. Suppression of HMGB1 or inhibition
HMGB1 cytosolic translocation diminished autophagic
protection in response to docetaxel. In addition, we
found that HMGB1 promoted Beclin-1-PI3K-III core
complex formation through the MEK/ERK1/2 pathway.
A variety of mechanisms underlying drug resistance
have been well established, such as DNA repair mecha-
nisms, drug export transporters and resistance to apop-
tosis [25]. Cancer cells exhibit multiple responses to
chemotherapy, including the initiation of cell survival
pathways and the activation of cell death pathways.Although previous studies considered autophagic cell
death as an alternative form of cell death due to exces-
sive self-digestion in the absence of apoptosis, over-
whelming evidence supports the idea that autophagy
functions primarily as a cell survival mechanism, especially
when cells are subjected to various stresses associated with
cell death [6]. Consistent with the documented cytopro-
tective role of autophagy in a number of cancer cells,
here we proved that blockade of autophagy potentiated
docetaxel-induced cell death in SPC-A1 and H1299
cells and resensitized the docetaxel-resistant SPC-A1/
DTX and H1299/DTX cells with a higher baseline level of
LC3-II to docetaxel to some extent. Our results clearly
revealed that autophagic activation is highly related to
docetaxel resistance in LAD cells. A detailed under-
standing of autophagy regulation in LAD might contrib-
ute to predict and overcome chemoresistance, thereby
improving therapeutic efficacy.
HMGB1 is generally located inside the nucleus in nor-
mally proliferating cells, and is released to the cytoplasm
and even extracellular space following different stimuli,
such as starvation, metabolic stress and chemotherapy,
in innate immune cells [26] as well as several types of
cancer cell lines [13,14]. Both endogenous and exogen-
ous HMGB1 have been considered as vital regulators of
autophagy in tumor cells [7,27]. Our focus here was the
interaction between endogenous HMGB1 and autoph-
agy. We observed that docetaxel promoted HMGB1
expression. Interestingly, we found a consistency in the
timing between cytosolic HMGB1 translocation and the
elevation of autophagic activity during the entire time
course of docetaxel treatment, suggesting that subcellular
localization of HMGB1 may correlate with autophagy
induction. Cytosolic translocation of HMGB1 as an origin
of autophagy has been demonstrated in other human cell
types in vitro and in vivo under various cytotoxic stresses
[28,29]. Our results showed that the basal level of au-
tophagy in docetaxel-resistant cells was decreased after
suppressing HMGB1 cytosolic translocation or knock-
down of HMGB1. However, disrupting HMGB1 cyto-
solic translocation had no apparent effect on autophagy
induction, even in HMGB1-overexpressing LAD parental
cells. These results proved that cytosolic translocation of
HMGB1 is likely a cause rather than an effect of autoph-
agy in LAD cells treated with docetaxel. In support of
this notion, inhibition of autophagy failed to abolish the
Figure 5 (See legend on next page.)
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Figure 5 HMGB1 regulated docetaxel-induced autophagy in parental LAD cells. (A) Whole cell lysates, nuclear exacts and cytoplasmic
fractions from both parentalcells transfected with control or HMGB1 shRNA followed by various concentrations of docetaxel treatment for a further 48 h
were subjected to western blot analysis for LC3, p62 and HMGB1. (B) SPC-A1 cells transfected with control or pcDNA3. 1-HMGB1 were treated with or
without 3-MA (5 mM, 2 h) before addition of docetaxel (10 μg/l). Total cell lysates, nuclear extracts, and cytoplasmic fractions were subjected to western
blot analysis for LC3, p62 and HMGB1. (C) SPC-A1 cells were co-transfected with either control or pcDNA3.1-HMGB1 and GFP-LC3 plasmid in the
presence or absence of 3-MA (5 mM, 2 h). Bar = 50 μm. Values are reported as mean ± S.D. of three independent experiments. *P < 0.05, **P < 0.01.
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as a pro-autophagic protein, while autophagy also regu-
lates release of HMGB1 following cytotoxic stress [8].
Nevertheless, we detected no obvious increase in the
level of HMGB1 in the extracellular environment. The
reason for failure of autophagy to enhance HMGB1
release in LAD cells exposed to docetaxel remains
unclear, but it is conceivable that the regulation be-
tween autophagy and HMGB1 is cell type-dependent
and may also be related to the agent in question.
Overexpression of HMGB1 is associated with six
hallmarks of cancer, including self-sufficiency in growth
signals and insensitivity to inhibitors of growth [30].
Depletion of HMGB1 greatly enhanced the sensitivity
to antitumor agents [31,32]. Consistent with these find-
ings, we confirmed that HMGB1 serves as a positive
regulator of autophagy and mediates docetaxel resist-
ance. Furthermore, inhibition of the cytosolic trans-
location of HMGB1 had similar effects on cytotoxicity
and autophagy disruption as knockdown of HMGB1 in
docetaxel-resistant cells, suggesting that cytosolic HMGB1
causes autophagic activation, which results in resistance to
docetaxel. As a pro-survival protein, HMGB1 promotes
cancer growth and development [33]. In our study,
reduced HMGB1 significantly inhibited tumor growth
following docetaxel treatment in vivo. Together these
data suggest that HMGB1 serves as a positive regulator
of autophagy and mediates the docetaxel resistance.
Emerging evidence has proven the role of Akt/mTORC1
pathway inhibition in the promotion of autophagy. How-
ever, we found that HMGB1 expression had only negli-
gible effects on the activity of Akt/mTORC1 signaling
both in SPC-A1 and SPC-A1/DTX cells. Moreover, sup-
pression of mTORC1 promoted autophagy in the control
vector group but not in the HMGB1-overexpressed group.
Autophagic stages, including induction, vesicle nucleation,
vesicle elongation and completion, are controlled by a
series of autophagy genes regulated by specific signaling
molecules [23]. Numerous investigations have indicated
that mTORC1 serves as a negative regulator of autophagy
induction [21]. However, our data found that inhibition
of mTORC1 failed to eliminate the effects of HMGB1
suppression on LC3-II conversion, suggesting that the
mTORC1-dependent pathway may not be required for
HMGB1-mediated autophagy and that HMGB1 might
regulate downstream autophagic steps.Furthermore, HMGB1 promotes Beclin-1-PI3K-III com-
plex formation, potentially through the MEK/ERK1/2
pathway. The PI3K family consists of three classes: I, II,
and III. PI3K-III activity is required for autophagic acti-
vation, while PI3K-I has a negative effect on autophagy
[5]. Beclin1 recruits PI3K-III to form the Beclin-1-PI3K-
III complex, thus triggering autophagosome nucleation
[24]. However, our results added another role for PI3K-
III in HMGB1-mediated autophagy. We demonstrated
that HMGB1 regulated autophagy through activating
the MEK/ERK1/2 pathway, while the genetic inhibition of
PI3K-III deprived the HMGB1-induced phosphorylation
of the MEK-ERK1/2 pathway and inhibited autophagic
activation. These results suggest that MEK/ERK1/2
signaling functions as a downstream signal of PI3K-III in
HMGB1-induced autophagy. The correlation between
PI3K and ERK was previously reported to regulate the
early onset of inflammatory pain [34]. An early study
demonstrated that co-targeted PI3K and MEK signaling
pathways enhanced cytotoxicity of histone deacetylase
inhibitors in NSCLC and chronic myeloid leukemia [35].
In addition, we verified that the activation of the MEK-
ERK1/2 signaling pathway was involved in HMGB1-
mediated formation of the Beclin-1-PI3K-III complex.
HMGB1 was shown to bind with Beclin-1, which then
promotes Beclin-1-PI3K-III complex formation [28].
However, the assembly of the complex appears to differ
in cell- and/or tissue-dependent manners [36]. A previ-
ous study indicated that ULK1-FIP200 complex forma-
tion is required for the interaction of this complex in
osteosarcoma cells [37]. We found that inhibition of
HMGB1 or MEK also limited the interaction between
Beclin-1 and PI3K-III. However, the negative regulation
of the Beclin-1- PI3K-III complex mediated by HMGB1
can be reversed after upregulation of MEK activity.
Together with data from the mechanistic studies, we
propose a model in which HMGB induces Beclin-1-
PI3K-III complex formation through activating the
MEK/ERK1/2 signaling pathway. Moreover, PI3K-III
also serves as an upstream signal of MEK/ERK1/2 for
facilitating the core complex formation in HMGB1-
regulated autophagy (Figure 9).
In summary, here we showed translocation of HMGB1
from the nucleus to the cytoplasm in response to doce-
taxel in LAD cells, which acts as a positive regulator
of autophagy that leads to diminished apoptosis and
Figure 6 HMGB1 regulated docetaxel-induced autophagy in docetaxel-resistant LAD cells. (A) Whole cell lysates, nuclear exacts and
cytoplasmic fractions from SPC-A1/DTX and H1299/DTX cells were treated with indicated doses of docetaxel in the presence or absence of EP
(10 mM, 1 h) were subjected to western blot analysis for LC3, p62 and HMGB1. (B) Both docetaxel-resistant cells were transfected with HMGB1
shRNA before treatment with the indicated doses of docetaxel for 48 h. Total cell lysates, nuclear extracts, cytoplasmic fractions were subjected to
western blot analysis for LC3, p62 and HMGB1. (C) Both docetaxel-resistant cells were co-transfected with either control or HMGB1 shRNA and
GFP-LC3 plasmid followed by treatment with docetaxel (100 μg/l) for an additional 24 h. Bar = 50 μm. Values are reported as mean ± S.D. of three
independent experiments. *P < 0.05, **P < 0.01.
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tion of Beclin-1-PI3K-III complex through activating
the MEK/ERK1/2 signaling pathway, thereby regulatingautophagosome formation. Our results support future
investigation of HMGB1 as a strategic target for LAD
therapy.
Figure 7 HMGB1 promoted Beclin-1-PI3K-III core complex formation through the MEK/ERK1/2 pathway. (A) SPC-A1 cells were transfected
with pcDNA3.1-HMGB1, PI3K-III siRNA or both for 48 h. Total cell lysates were subjected to western blot analysis of LC3, p62, p-ERK1/2 and
GAPDH (as a loading control). (B, E) SPC-A1 cells were pretreated with PD098059 (20 μg/ml, 45 min), followed by transfection with control or
pcDNA3.1-HMGB1. Whole cell lysates were analyzed by (B) western blot against LC3, p62, and p-ERK1/2 and (E) immunoprecipitation (IP) as
described in Materials and methods. (C) SPC-A1 cells were transfected with pcDNA3.1-HMGB1, MEK siRNA or both for 48 h. Total cell lysates
were examined by western blot analysis using specific antibodies against LC3, p62, MEK and p-ERK1/2. (D, F) SPC-A1 cells were transfected with
control or HMGB1 shRNA, and then infected with the constitutively active MEK1 construct, MEK1-DD. Total cell lysates were analyzed by (D) western
blot for LC3, p62 and p-ERK1/2 and (F) IP. The blots shown are representative of three separate experiments in which similar results were observed.
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Figure 8 Suppression of HMGB1 resensitized docetaxel-resistant SPC-A1/DTX cells to docetaxel in vivo. (A) NOD/SCID mice were
inoculated with 5.0 × 106 SPC-A1/DTX cells following transfection of control or HMGB1 shRNA and treated with docetaxel (1 mg/kg) beginning
at day 6. Tumor volumes were calculated for 14 days. (n = 5; *P < 0.05). (B) Representative photographs of tumors formed at 2 weeks after
subcutaneous transplantation are shown. (C) Hematoxylin and eosin (H&E)-stained, proliferating cell nuclear antigen (PCNA)-stained and TUNEL assay
stained sections of the transplanted tumors are shown (original magnification, ×400). (D) HMGB1 and LC3 expression in the transplanted tumors were
determined by western blot analysis.
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Cell lines and reagents
Human LAD cell lines SPC-A1 and H1299 were purchased
from the Tumor Cell Bank of Chinese Academy of Medical
Science (Shanghai, China) and cultured in RPMI 1640
medium containing 10% fetal bovine serum and ampicillin
and streptomycin at 37°C in a humidified atmosphere of
95% air and 5% CO2. Docetaxel-resistant SPC-A1 and
H1299 cell lines (SPC-A1/DTX and H1299/DTX) were
established and preserved in 50 μg/L final concentration of
docetaxel in our laboratory. Antibodies against GAPDH,
LC3, p62, caspase3, activated (cleaved) caspase3 (c-cas-
pase3), PARP, cleaved PARP (c-PARP), Atg5, HMGB1,
mTOR, phosphorylated mTOR (p-mTOR), Akt, p-Akt,
S6RP, p-S6RP, MEK, ERK1/2, p-ERK1/2, and H2A were
obtained from Cell Signaling Technology. Bafilomycin A1, 3-
methyladenine (3-MA), ethyl pyruvate (EP) and PD098059
were purchased from Sigma Aldrich (St. Louis, MO).
cDNA constructs, siRNA and transfection
The GFP-tagged LC3 cDNA expression construct was
a gift from Dr. Noboru Mizushima (Tokyo Medical
and Dental University, Tokyo, Japan). P-Babe-Puro-MEK-
DD, which constitutively expresses activated MEK1-
DD (S218D/S222D), was purchased from Addgene Inc.
(Cambridge, MA). Transfections with pcDNA3.1-HMGB1,
HMGB1 shRNA, Atg5 siRNA, mTOR siRNA, PI3K-III
siRNA and MEK siRNA (all obtained from GenePharma,
Shanghai, China) were performed using Lipofectamine 2000
(Invitrogen, USA), according to the manufacturer’s protocol.
Cell viability
Cells were cultured in 96-well plates with 100 μl medium
per well and treated with the indicated drug combination
for 48 h. MTT (5 mg/ml, 20 μl) was added to each wellFigure 9 Model depicting the mechanism by which HMGB1 modulate
promotes the cytosolic translocation of HMGB1. Cytosolic HMGB1 acts as a
Beclin-1-PI3K-III complex through activating the MEK/ERK1/2 signaling pat
facilitating the core complex formation.and cells were incubated for 4 h at 37°C. The media was
removed and 100 μl of DMSO was added per well to
solubilize the formazan product. The relative number of
surviving cells in each group was determined by measur-
ing the optical density (O.D.) of the cell lysates at 560 nm.
Colony formation assay
Cells were plated in triplicate (800 cells/well) in 6-well
plates for approximately 24 h under standard conditions.
After specific treatments, the cells then were exposed to
various doses of docetaxel. After 14 days of incubation,
the colonies were fixed with methanol, stained with 0.5%
crystal violet in absolute ethanol, and colonies with ≥50
cells were counted under a dissection microscope. In
each irradiation dose group, the surviving fraction of
cells was calculated as plating efficiency of the irradiated
cells divided by the plating efficiency of the irradiated
cells by that of mock control.
Preparation of subcellular fractions and western blot
analysis
Cytosolic extracts, nuclear extracts, extracellular medium
and total cellular lysates were prepared using the NE-PER
nuclear and cytoplasmic extraction kit (Piece, Rockford,
USA) according to the manufacturer’s instructions. Protein
concentrations of the extracts were measured with BCA
assay (Pierce, Rockford, USA) and equalized with the ex-
traction reagents. Equal amount of the extracts were loaded
and subjected to SDS-PAGE, transferred onto nitrocellulose
members, and analyzed as described previously [38].
Immunoprecipitation analysis
Cells were lysed at 4°C in RIPA buffer (Millipore). Samples
containing equal amounts of proteins were precleared
with protein A sepharose (Millipore) and subsequentlys docetaxel resistance by regulating autophagy. Docetaxel
n activator of autophagy, which potentiates the formation of the
hway. PI3K-III also serves as an upstream signal of MEK/ERK1/2 for
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antibodies in the presence of protein A sepharose beads.
The beads were washed three times with RIPA buffer,
and the immune complexes were eluted from the beads
and subjected to SDS-PAGE and western blot analysis.
Apoptosis assay
We measured apoptosis using an Annexin-V-fluorescein
isothiocyanate apoptosis detection kit (Oncogene Research
Products, Boston, MA) that quantitatively measures the
percentage of early apoptotic cells via flow cytometric
analysis. In addition, western blot analysis for c-PARP
and c-caspase3 after various treatments was performed.
The degree of apoptosis in tissue was assessed with the
TUNEL kit (Roche) according to the manufacturer’s
instructions.
GFP-LC3 analysis
Cells were transfected with a GFP-LC3-expressing plas-
mid. After 24 h, cells were fixed in 3.7% formaldehyde for
20 min, washed with PBS, mounted and inspected using a
fluorescence microscope. A minimum of 150 GFP-positive
cells were counted under each condition, and the graphs
were plotted as percentage of GFP-LC3 positive cells over
total transfected cell population.
Transmission electron microscopy
Cells were fixed with a solution containing 3% glutaral-
dehyde plus 2% paraformaldehyde in 0.1 mol/L phosphate
buffer (pH 7.4), followed by 1% OsO4. After dehydration,
thin sections were stained with uranyl acetate and lead
citrate for observation under a JEM 1011CX electron
microscope (JEOL, USA, Inc.) Digital images were
obtained using an Advanced Microscopy Techniques
imaging system.
Mice xenograft models and immunohistochemistry
analysis
All animal experiments strictly followed the guidelines
of the Institutional Review Board of Jinling Hospital. Ap-
proximately 5.0 × 106 SPC-A1/DTX/shcontrol or SPC-
A1/DTX/ shHMGB1 cells were suspended in 100 μl PBS
and injected subcutaneously into the right side of the
posterior flank of female BALB/c athymic nude mice
(Department of Comparative Medicine, Jinling Hospital,
Nanjing, China) at 5 to 6 weeks of age. Tumor volumes
were examined every other day and were calculated
using the equation: V = A × B2/2(mm3), where A is the
largest diameter and B is the perpendicular diameter.
When the average tumor size reached approximately
50 mm3, docetaxel was administered via intraperitoneal
injection at a dose of 1 mg/kg at one dose every other
day with for three total doses [39]. After 2 weeks, all
mice were killed, and necropsies were performed. Theprimary tumors were excised and analyzed by hematoxylin
and eosin (H&E) staining, immunohistochemistry staining
of proliferating cell nuclear antigen (PCNA) [40], TUNEL
staining [41] and western blot analysis for LC3 and
HMGB1 protein expression.Statistical analyses
Statistical analyses and data plotting were performed
using SigmaPlot software version 12. Results were pre-
sented as mean ± S.D. of three independent experiments
and analyzed with the Student’s t test. P < 0.05 was con-
sidered statistically significant for all analyses.Additional files
Additional file 1: Figure S1. Inhibition of autophagy enhanced
apoptosis of LAD cells in response to docetaxel. (A, B) SPC-A1 and H1299
cells were treated with docetaxel (10 μg/l) in the presence or absence of
3-methyladenine (3-MA, 5 mM, 2 h) or Atg5 siRNA. Western blot analyzed
the expression of LC3, p62, cleaved-PARP (c-PARP) and cleaved caspase3
(c-caspase3). (C, D) SPC-A1/DTX and H1299/DTX cells were treated with
indicated doses of docetaxel in the presence or absence of 3-MA or Atg5
siRNA. Whole cell lysates were subjected to western blot analysis of LC3,
p62, c-PARP and c-caspase3 . GAPDH was used as an internal control.
Additional file 2: Figure S2. Docetaxel promoted HMGB1 expression
and cytosolic translocation. (A) H1299 cells were treated with docetaxel
(10 μg/l) for the indicated periods. Total cell lysates, nuclear extracts,
cytoplasmic fractions and extracellular medium were prepared and
HMGB1 levels were analyzed by western blot. (B) H1299 cells were
pretreated with or without ethyl pyruvate (EP, 10 mM, 1 h) before
addition of docetaxel (10 μg/l) for 48 h. Whole cell lysates, nuclear
extracts and cytoplasmic fractions were analyzed by western blot for
HMGB1. (C) H1299 cells transfected with pcDNA3.1-HMGB1 or control
vector were treated with EP (10 mM, 1 h). Total cell lysates, nuclear
extracts, cytoplasmic fractions were analyzed by western blot for HMGB1.
GAPDH was used as a loading control for whole cell lysates, extracellular
medium and cytoplasmic extracts, and H2A was used as a loading
control for nuclear extracts. The experiments were performed in triplicate.
Additional file 3: Figure S3. Knockdown of HMGB1 increased
apoptosis of LAD cells in response to docetaxel. After transfection with
control or HMGB1 shRNA for 48 h, (A) parental and (B) docetaxel-resistant
LAD cells were exposed to docetaxel (50 μg/l and 100 μg/l) for an additional
48 h with or without Z-VAD-fmk (20 μmol/L, 1 h) pretreatment. Apoptosis
was evaluated by western blot analysis of c-PARP and c-caspase3.
Additional file 4: Figure S4. mTORC1-dependent pathway was not
required for HMGB1-mediated autophagy. (A) SPC-A1 cells with
overexpressed HMGB1 and (B) SPC-A1/DTX cells silenced for HMGB1
were subjected to western blot analysis of p-Akt(Ser473), p-mTOR
(Ser2448) and p-S6RP. (C) SPC-A1 cells were pretreated with or without
rapamycin (50 mM, 2 h) before transfection with control or HMGB1
shRNA. (D) SPC-A1 cells were co-transfected with either control or
HMGB1 shRNA and mTORC1 siRNA. Whole cell lysates were subjected
to western blot analysis of p-mTOR(Ser2448), LC3 and p62. GAPDH
was used as a sample loading control. The figures show a representative
experiment of three separate experiments with similar results.Abbreviations
LAD: Lung adenocarcinoma; NSCLC: Non-small cell lung cancer;
HMGB1: High-mobility group box 1; MEK: Mitogen-activated protein kinase;
ERK: Extracellular signal-regulated kinase; 3-MA: 3-methyladenine;
siRNA: Small interfering RNA; EP: Ethyl pyruvate; p70S6K: 70 kDa ribosomal
protein S6 kinase; H&E: Hematoxylin and eosin; PCNA: Proliferating cell
nuclear antigen.
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